MEK114267, A Phase III randomised, open-label study comparing GSK 1120212 to chemotherapy in subjects with advanced or metastatic BRAF V600E/K mutation-positive melanoma.

Project Details

Short titleMEK114267, A Phase III randomised, open-label study comparing GSK 1120212 to chemotherapy in subjects with advanced or metastatic BRAF V600E/K mutation-positive melanoma.
StatusFinished
Effective start/end date28/03/11 → 31/12/17

Funding

  • Queen Elizabeth Hospital Birmingham